Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Washington University School of Medicine
With
American Academy of Pediatrics
Ambulatory Pediatric Association
We hypothesized that children with moderate acute asthma exacerbations receiving oral montelukast in addition to standard therapy will have at least 12% greater FEV1 improvement in three hours than those receiving standard therapy alone.
In this randomized double-blind placebo-controlled study, we enrolled emergency patients aged 6-14 years with moderate acute asthma exacerbations (initial PEFR 40-70% predicted). Subjects received montelukast 5-mg or placebo orally then standard therapy consisting of weight-based doses of nebulized albuterol, nebulized ipratropium bromide, and oral corticosteroids. We measured FEV1 before study medication administration and hourly for three hours.
We conducted a planned an interim analysis after approximately one-half of the estimated sample had been enrolled.
Age
6–14
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Seeking care in ED for acute asthma exacerbation
Age 6-14 years inclusive
Initial FEV1 = 40-70% predicted (defined as moderate severity)
Consent to participate in study
You may not be if
Severe exacerbation requiring immediate therapy as determined by treating clinician